Immix Biopharma (IMMX) price target increased by 25.64% to 16.66

The article says convicted fugitive former doctor Ronald Fischer, 70, appeared in Rhode Island court under an alias, after being arrested in July 2024 while working as Chief Medical Officer for Immix Biopharma. It reports Immix filed an SEC Form 8-K stating “Richard Graydon” was terminated and is no longer with the company, and that shareholder law firms are investigating hiring practices.

US Marshals said fugitive Richard Fischer used the alias Richard Graydon, which matches a doctor and biotech executive Immix Biopharma hired as chief medical officer in March. Immix told the SEC it terminated Graydon on Friday for reasons unrelated to company activities. Immix removed his bio and a hiring press release; STAT could not verify his resume.

Investing.com reports Immix Biopharma (IMMX) shares fell 11.6% in morning trading after STAT News said the company’s CMO hired in March 2026 under “Dr. Richard Graydon” was actually Ronald Fischer, a fugitive arrested in July 2026. Immix said in an 8-K that “Graydon” was terminated. The drop came ahead of NEXICART-2 trial topline data in Q3 2026.

Immix Biopharma Inc (NASDAQ:IMMX) shares fell about 13% after STAT News reported that a fugitive, Ronald Fischer, appeared to have worked for the company under the name Richard Graydon. Immix terminated Graydon via an 8-K, saying the firing is unrelated to his activities and expects no material business impact.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.